Tempus AI, Inc. (TEM) Down 6.3% — Is It Time to Call It Quits?
Tempus AI, Inc. (TEM) gave back meaningful ground in today's session, shedding $4.57 to close at $68.12 on the NASDAQ. The session's decline comes after an extraordinary run—TEM surged roughly 39.5% during the prior week alone, gaining approximately 18% across just two sessions on August 20–21. Monday's pullback pulls shares further from the 52-week high of $104.32 reached on October 9, 2025, leaving TEM now sitting about 34.7% below that peak and closer to the lower end of its $40.77–$104.32 annual range.
Volume for the session came in at approximately 4.3 million shares, running meaningfully below the 90-day average of roughly 6.5 million. The lighter turnover alongside a sharp price decline suggests sellers were not rushing to exit in panic, but rather that buyers failed to show up with enough conviction to absorb the post-rally overhang. The reduced participation adds a note of caution to any near-term recovery thesis.
Why Tempus AI, Inc. Price is Moving Lower
Monday's decline looks like a textbook profit-taking episode following an unusually compressed rally. The catalyst for that rally traces back to August 19, when Merck (MRK) and Moderna (MRNA) reported positive Phase 3 cancer-vaccine results—a development that drew immediate investor attention to Tempus's planned acquisition of Personalis, whose tumor-profiling technology contributed to that research program. TEM responded sharply, gaining roughly 18% across August 20–21 as investors priced in the strategic value of a Personalis tie-up in an environment suddenly energized by oncology-vaccine momentum. By August 24, however, with shares still valued at approximately 9 times sales after that rapid ascent, investors appear to have concluded that the risk/reward no longer justified holding through the elevated premium—and began locking in gains.
It's worth noting that the fundamental backdrop from Tempus's most recent earnings release is not the issue driving today's move. On July 30, the company reported Q2 revenue of $382.5 million, edging past the $379.7 million consensus and representing 21.6% year-over-year growth. Non-GAAP EPS came in at a $0.04 loss against a consensus estimate of a $0.14 loss—a material beat on the bottom line. GAAP net income of $5.6 million marked a dramatic improvement from a $42.8 million loss a year earlier, and gross margin expanded to 64.4% from 62.0%. Management also raised its 2026 revenue guidance following the quarter. None of that has changed—what has changed is the price, which quickly ran well ahead of where even optimistic fundamental models could comfortably anchor.
The valuation question is the crux of today's hesitation. At roughly 9 times sales and with no clear path to near-term GAAP profitability despite improving unit economics, TEM remains a stock that rewards momentum investors and penalizes late arrivals. With the prior week's 39.5% gain having reversed much of a prior decline in compressed fashion, some degree of consolidation or retracement was a logical outcome. The broader Health Care sector offers little additional support, and peers operating in adjacent genomics and oncology spaces—including Natera, Inc. (NTRA, D-) and Revolution Medicines, Inc. (RVMD, D-)—carry similarly cautious ratings, underscoring that risk appetite in this corner of Health Care remains selective and fragile.
What is the Tempus AI, Inc. Rating - Should I Sell?
Weiss Ratings assigns TEM a D- rating. The rating was upgraded on 8/12/2026. Current recommendation is Sell.
Even after the recent upgrade, the D- reflects a risk profile that remains difficult to defend on a fundamental basis. Revenue growth of 21.56% is a genuine positive and earns a Fair Growth Index—meaningful for a healthcare technology platform still in its scaling phase, but not enough on its own to offset the structural challenges visible elsewhere in the scorecard. The Good Solvency Index indicates the balance sheet is not an immediate crisis point, which matters for a company still burning cash and navigating a capital-intensive acquisition strategy.
The weak side of the ledger is harder to dismiss. A profit margin of -17.76% and the Very Weak Efficiency Index reflect the reality that Tempus has not yet translated its revenue expansion into operating leverage—costs remain elevated relative to what the top line is generating, a persistent challenge for a business investing heavily in data infrastructure, laboratory capacity, and AI development simultaneously. The Weak Total Return Index and Weak Volatility Index together characterize what investors actually experience holding TEM: returns that have been inconsistent, punctuated by sharp moves in both directions, and with downside risk that is difficult to hedge at current valuation levels. A forward P/E of -50.43 is not a valuation anchor in any conventional sense—it simply reflects that earnings remain negative and that any premium being paid is a bet on future profitability that has not yet arrived.
Within the Health Care sector, Tempus AI sits alongside Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), Revolution Medicines, Inc. (RVMD, D-), and BeOne Medicines AG (ONC, D-), and below Chugai Pharmaceutical Co., Ltd. (CHGCF, D). That peer grouping is not an encouraging neighborhood—it reflects a segment of Health Care where risk is elevated, near-term fundamentals are strained, and the investment case depends heavily on outcomes that remain speculative. The upgrade on August 12 is a step in the right direction, but a D- is still a Sell, and the current price—especially after a 39.5% weekly surge—makes a cautious stance difficult to argue against.
About Tempus AI, Inc.
Tempus AI, Inc. (TEM) is a Health Care company headquartered in Chicago, Illinois, built around the application of artificial intelligence and large-scale multimodal data to clinical decision-making and life sciences research. The company operates what it describes as a closed-loop platform that integrates directly with clinician workflows, connecting laboratory diagnostics, an analytics engine, and a repository of linked clinical, molecular, and imaging data into a unified system. That architecture is designed to reduce the gap between raw genomic data and actionable clinical insight, positioning Tempus as infrastructure rather than a point solution within the precision medicine ecosystem.
On the diagnostics side, Tempus offers next-generation sequencing tests including its core xT and xR assays, which deliver large-panel DNA and RNA analysis, full transcriptome profiling, and germline findings from standard blood or saliva samples. The company also provides PCR profiling, anatomic and molecular pathology services, pharmacogenomic testing for psychiatric conditions through its nP assay, and tumor-derived biological modeling through its Organoids program. These capabilities are complemented by Trials, a clinical trial matching service, and Algos, an algorithm-based diagnostics application—products that extend Tempus's reach deeper into both the physician's office and the drug development pipeline.
For life sciences customers, Tempus offers Lens, a software application enabling advanced precision research, and Insights, which licenses de-identified, linked clinical and molecular data libraries to pharmaceutical and biotech partners. Strategic collaborations with AstraZeneca, GlaxoSmithKline, Merck, and Recursion Pharmaceuticals underscore the company's role as a data and analytics partner to major drug developers—a positioning that has become more visible with Merck and Moderna's oncology vaccine progress and the planned acquisition of Personalis. The breadth of Tempus's platform across diagnostics, data licensing, and AI-driven tools gives it a differentiated footprint in precision medicine, though converting that footprint into consistent profitability remains the central challenge.
Investor Outlook
Tempus AI, Inc. (TEM) carries a Weiss Rating of D- (Sell), reflecting persistent profitability challenges and elevated valuation risk even as top-line growth trends improve. Investors should watch whether the Personalis acquisition closes on favorable terms and how management balances ongoing cash consumption with the pace of gross margin expansion—two variables that will most directly influence any future rating trajectory. See full rankings of all D--rated Health Care stocks inside the Weiss Stock Screener.
--